FDA Approved: TAFINLAR — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for TAFINLAR (dabrafenib) from Novartis Pharmaceuticals Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• TAFINLAR (DABRAFENIB)

Snippet

SUPPL AP for TAFINLAR (DABRAFENIB)